In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment for ...

In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment for autoimmune ...

Savara (SVRA) “announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will ...

At close: April 8 at 4:00:01 p.m. EDT ...